The XRP Ledger's latest software fix package has secured the 29 validator votes needed for approval and could activate on October 23 if support holds. This update addresses various transaction and vault-related bugs but does not enable the planned lending system, which remains short of the required votes. The lending proposals, including fixed-term loans without collateral assessed by brokers, need more validator support before activation. The update improves network stability ahead of the lending feature's future launch.
The XRP Ledger's software fix nears approval while lending launch remains on hold; for readers following the broader crypto market, here is Pluang's snapshot as of Oct 19, 2026 14:01 WIB: Of 50 major cryptocurrencies priced on Pluang, 36 rose and 13 fell today. Notable movers include ENJ at Rp490 with a 1-day change of -2.36% and Pluang order activity heavily skewed to 95% Sell, MANA at Rp1.529 down 2.30% with a near-even buy/sell split, and DOT at Rp20.204 up 2.25% with strong buy interest at 89%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
